Hong Kong, Sept. 02, 2026 (GLOBE NEWSWIRE) — Ming Shing Group Holdings Limited (the “Company” or “Ming Shing”) (NASDAQ: PMA), a Hong Kong-based company mainly engaged in wet trades works whose mission it is to become the leading wet trades works service provider in Hong Kong, announces a significant update in its business development. Ming Shing is pleased to announce that it has closed the acquisition of Meals Through Seasons Limited. As previously reported, on August 11, 2026, the Company entered into a stock purchase agreement (the “SPA”) to acquire he entire issued share capital of Meals Through Seasons Limited, a business company incorporated under the laws of the British Virgin Islands (the “Target Company”), with Hongs Smart Limited and Yapjianhuei Smart Limited (each a “Seller” and, collectively, the “Sellers”), the Target...

HOUSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) — Kayne Anderson Energy Infrastructure Fund, Inc. (the “Company”) (NYSE: KYN) today provided a summary unaudited statement of assets and liabilities and announced its net asset value and asset coverage ratios under the Investment Company Act of 1940 (the “1940 Act”) as of August 31, 2026. As of August 31, 2026, the Company’s net assets were $2.9 billion, and its net asset value per share was $17.00. As of August 31, 2026, the Company’s asset coverage ratio under the 1940 Act with respect to senior securities representing indebtedness was 640% and the Company’s asset coverage ratio under the 1940 Act with respect to total leverage (debt and preferred stock) was 502%.STATEMENT OF ASSETS AND LIABILITIESAUGUST 31, 2026 // (UNAUDITED)     (in millions)Investments   $ 4,070.2  Cash...

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights08/31/2026   314,388,807     Total gross of voting rights: 314,388,807  Total net* of voting rights: 314,222,095* Net total = total number of voting rights attached to shares – shares without voting rightsAttachmentPDF Version

TORONTO, Sept. 02, 2026 (GLOBE NEWSWIRE) — Inventus Mining Corp. (TSXV: IVS) (“Inventus” or the “Company”) announces that it has granted 3,400,000 incentive stock options to certain officers, directors, employees, and consultants of Inventus Mining effective September 2, 2026. The options are exercisable at a price of $0.295 per share for a period of five years and have been issued under the Company’s 10% rolling stock option plan. The options vest one-third at each of 6, 12, and 18 months from the date of grant. All stock options are subject to the acceptance by the TSX Venture Exchange. For further information visit www.inventusmining.com, or contact: Wesley WhymarkCEO & DirectorInventus Mining Corp.E-mail: wesley@inventusmining.com Phone: 705-822-3005 Social Media Accounts X: https://x.com/InventusMiningLinkedIn: https://ca.linkedin.com/company/inventus-miningYouTube:...

Results support the clinical rationale for RASolve 301, an ongoing Phase 3 trial in RAS mutant metastatic non-small cell lung cancerREDWOOD CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that The New England Journal of Medicine (NEJM) has published a report describing data from the Phase 1/2 clinical trial evaluating RASONQUE (daraxonrasib), an oral, RAS(ON) multi-selective inhibitor, in patients with previously treated advanced RAS mutant non-small cell lung cancer (NSCLC). “RAS mutations are among the most common oncogenic drivers in lung cancer, occurring in approximately 30 percent of cases. Targeted RAS inhibition...

MELVILLE, N.Y., Sept. 02, 2026 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (Nasdaq: BRTX) (“BioRestorative” or the “Company”), a late-stage clinical regenerative medicine company, today announced that the Company’s Board of Directors approved a 1-for-20 reverse stock split (the “Reverse Stock Split”) of the Company’s common stock (the “Common Stock”). The Company was not required to obtain stockholder approval to effectuate the Reverse Stock Split under Nevada law. The Company filed a certificate of change with the Secretary of State of the State of Nevada, which is expected to become effective as of 4:30 P.M. Eastern Time on September 7, 2026. The Common Stock will begin trading on The Nasdaq Capital Market on a reverse split-adjusted basis at the start of trading on September 8, 2026, under the symbol “BRTX” and under a...